• Bronchial hyperresponsiveness, number of symptom free days and nights, number of exacerbations, time to first exacerbation, time to increase of study medication
• 1. Bronchial hyper-responsiveness both change from baseline and change in values at the end of the study.
• 2. Number of symptom-free days and nights without use of rescue medication.
• 3. Number of exacerbations. 4. Time to first exacerbation. 5. Time to increase of study medication

An 18 months randomised double-blind study with two parallel arms with start dose of inhaled SERETIDE 50/100mcg BD or FLIXOTIDE 100mcg BD, Phase I is 6 months where the patient will be up-titrated until well controlled is achieved, After 6 months the treatment continues without changes during 9 months = PhaseII. The aim is to investigate and evaluate the assumption that the combination therapy with SERETIDE controls mild persistent asthma better than inhaled corticosteroids(FLIXOTIDE) alone.

• Drug: Seretide
• Drug: Flixotide

Inclusion Criteria:

• Willing to give informed consent.
• Males or females aged 18-70.
• Able to understand and complete dairy cards.

• Mild persistent asthma according to GINA. In addition, at randomisation subjects were required to have:

  1. Day time symptoms more than once a week but not every day. 2. Night-time symptoms not more than once a week. 3. FEV1 >80% predicted 4.

PC20 <8mg/mL

Exclusion Criteria:

• Change to regular asthma medication in 4-weeks prior to visit 1.
• Use of oral, depot or parenteral corticosteroids within 8 weeks of visit 1.
• Lower respiratory tract within 4 weeks of Visit 1
• Received investigational study drug within 4 weeks of visit
• Smoking history of >10 pack years of more.
• Serious uncontrolled disease.
• Medical conditions or medications known to affect the assessments or endpoints.
• Evidence of alcohol or drug abuse.
• Known pregnancy or planned pregnancy.
• Known or suspected hypersensitivity to inhaled corticosteroids, beta-agonists or lactose.
• Previous enrollment in the study